单剂量帕博利珠单抗后的多种自身免疫并发症
Multiple Autoimmune Complications After a Single Dose of Pembrolizumab.
作者信息
Ahdi Hardeep S, Abdulmujeeb Sufyan, Nabrinsky Edward
机构信息
Internal Medicine, Advocate Lutheran General Hospital, Park Ridge, USA.
Internal Medicine, Advocate Sherman Hospital, Elgin, USA.
出版信息
Cureus. 2023 Mar 7;15(3):e35871. doi: 10.7759/cureus.35871. eCollection 2023 Mar.
Pembrolizumab, a monoclonal antibody that inhibits programmed cell death protein-1 (PD-1), is an important treatment for various malignancies. Unfortunately, it has also been associated with a wide array of immune-related adverse events. We present a unique case of a patient who received a single dose of pembrolizumab and subsequently developed multiple immune-mediated complications, including dermatitis, hepatitis, myositis, myocarditis, and myasthenia gravis.
帕博利珠单抗是一种抑制程序性细胞死亡蛋白-1（PD-1）的单克隆抗体，是治疗多种恶性肿瘤的重要药物。不幸的是，它也与一系列免疫相关不良事件有关。我们报告了一例独特的病例，该患者接受了单剂量帕博利珠单抗治疗，随后出现了多种免疫介导的并发症，包括皮炎、肝炎、肌炎、心肌炎和重症肌无力。
Zotero 插件